We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dopamine Reuptake Inhibitors of Cocaine Abuse - 1

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000276
First Posted: September 21, 1999
Last Update Posted: July 25, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University
  Purpose
The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Bupropion Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Dopamine Reuptake Inhibitors of Cocaine Abuse

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Side effects
  • Cocaine effects

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000276


Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000276     History of Changes
Other Study ID Numbers: NIDA-09250-1
P50DA009250 ( U.S. NIH Grant/Contract )
P50-09250-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: July 25, 2013
Last Verified: December 2008

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Bupropion
Cocaine
Dopamine Uptake Inhibitors
Dopamine
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Protective Agents